These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 23231932)

  • 1. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
    Cohen SM; Mukerji R; Timmermann BN; Samadi AK; Cohen MS
    Am J Surg; 2012 Dec; 204(6):895-900; discussion 900-1. PubMed ID: 23231932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
    BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of estrogen receptor-alpha and rearranged during transfection tyrosine kinase is associated with withaferin a-induced apoptosis in MCF-7 breast cancer cells.
    Zhang X; Mukerji R; Samadi AK; Cohen MS
    BMC Complement Altern Med; 2011 Oct; 11():84. PubMed ID: 21978374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.
    Koh YW; Shah MH; Agarwal K; McCarty SK; Koo BS; Brendel VJ; Wang C; Porter K; Jarjoura D; Saji M; Ringel MD
    Endocr Relat Cancer; 2012 Feb; 19(1):29-38. PubMed ID: 22109971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
    Chen G; Nicula D; Renko K; Derwahl M
    Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro].
    Chen FS; Cui YZ; Luo RC; Wu J; Zhang H
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1684-7. PubMed ID: 18819900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.
    Henderson YC; Ahn SH; Kang Y; Clayman GL
    Clin Cancer Res; 2008 Aug; 14(15):4908-4914. PubMed ID: 18676765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
    Wei G; Wang M; Hyslop T; Wang Z; Carr BI
    Int J Cancer; 2010 Dec; 127(12):2949-58. PubMed ID: 21351273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
    Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.
    Tesei A; Leonetti C; Zupi G; Scarsella M; Brigliadori G; Ulivi P; Fabbri F; Arienti C; Amadori D; Passardi A; Silvestrini R; Zoli W
    J Cell Mol Med; 2011 Feb; 15(2):316-26. PubMed ID: 20015197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
    Abdulghani J; Gokare P; Gallant JN; Dicker D; Whitcomb T; Cooper T; Liao J; Derr J; Liu J; Goldenberg D; Finnberg NK; El-Deiry WS
    Clin Cancer Res; 2016 Dec; 22(24):6192-6203. PubMed ID: 27307592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
    Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA
    Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inhibitory effect of sorafenib combined with arsenic trioxide on hepatocellular carcinoma cells].
    Wu J; Luo RC; Zhang H; Cui YZ
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):639-41. PubMed ID: 18495609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
    Bil J; Zapala L; Nowis D; Jakobisiak M; Golab J
    Cancer Lett; 2010 Feb; 288(1):57-67. PubMed ID: 19632769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells.
    Schult C; Dahlhaus M; Ruck S; Sawitzky M; Amoroso F; Lange S; Etro D; Glass A; Fuellen G; Boldt S; Wolkenhauer O; Neri LM; Freund M; Junghanss C
    BMC Cancer; 2010 Oct; 10():560. PubMed ID: 20950443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
    Peng CL; Guo W; Ji T; Ren T; Yang Y; Li DS; Qu HY; Li X; Tang S; Yan TQ; Tang XD
    Cancer Biol Ther; 2009 Sep; 8(18):1729-36. PubMed ID: 19633425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways.
    Kandil E; Tsumagari K; Ma J; Abd Elmageed ZY; Li X; Slakey D; Mondal D; Abdel-Mageed AB
    J Surg Res; 2013 Oct; 184(2):898-906. PubMed ID: 23602735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic activity of letrozole and sorafenib on breast cancer cells.
    Bonelli MA; Fumarola C; Alfieri RR; La Monica S; Cavazzoni A; Galetti M; Gatti R; Belletti S; Harris AL; Fox SB; Evans DB; Dowsett M; Martin LA; Bottini A; Generali D; Petronini PG
    Breast Cancer Res Treat; 2010 Nov; 124(1):79-88. PubMed ID: 20054642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
    Tran MA; Smith CD; Kester M; Robertson GP
    Clin Cancer Res; 2008 Jun; 14(11):3571-81. PubMed ID: 18519791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage.
    Mondal A; Bennett LL
    Biomed Pharmacother; 2016 Dec; 84():1906-1914. PubMed ID: 27863838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.